Clinical Trial Update: Subcutaneous Botulinum Toxin for Cutaneous Allodynia [NA]

View source ↗

Summary

A Stanford-sponsored clinical trial evaluated subcutaneous botulinum toxin for cutaneous allodynia; the study is completed and its results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Allodynia

Drugs mentioned

• Botulinum toxin (botulinum toxin)

Snippet

Sponsor: Stanford University | Conditions: Pain | NA | Status: COMPLETED | Results posted: 2017-10-25